ArticleScientific reports2026
Abnormal elevated PANX1 expression hampers endometrial decidualization by upregulating extracellular ATP concentration in patients with recurrent implantation failure.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent implantation failure (RIF), a important contributor to infertility in assisted reproductive technologies, is believed to be primarily to abnormal endometrial decidualization. However, its related molecular mechanisms are still incompletely clear. It has been reported that PANX1 is an ATP-permeable channel to regulate the extracellular ATP, and ATP level could influence the progress of endometrial decidualization. Therefore, we conduct this study to explore the potential role of PANX1 during the development of RIF. In this study, we first compared the the expression of PANX1 in RIF patients and control patients. Then, the human endometrial stromal cells (HESCs) was used to the explore the regulatory function of PANX1 on endometrial decidualization by Immunofluorescence staining, Western blot, RT-PCR, Plasmid transfection and ATP detection. Finally, animal model was established to further confirm the results which were found in vitro. We observed a significant upregulation expression of ATP release channel protein Pannexin1 (PANX1) in endometrial tissue of RIF patients. Moreover, after overexpressing PANX1 in human endometrial stromal cells (HESCs), we found a significantly high concentration of extracellualr ATP (eATP) and the inhibition of HESCs decidualization, which was characterized as the decreasing expression of prolactin (PRL) and insulin-like growth factor binding protein 1 (IGFBP-1), as well as the aberrant morphologic cytoskeletion of HESCs. Surprisingly, knockdown the expression of PANX1 in HESCs also impaired the cellular decidualization, indicating the important role of normal PANX1 expression during the process of endometrial decidualization. The subsequent animal study further confirmed our findings in vitro. The present study clearly showed that abnormal high expression of PANX1 hindered endometrial decidualization through the upregulation of eATP concentrations, ultimately leading to embryo implantation failure. Our findings suggested a novel cause of RIF and identified a potential therapeutic target for RIF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.